SurksMI, ChopraIJ, MariashCN. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA1990; 263: 1529–32.
2.
JonklaasJ, BiancoAC, BauerAJ. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid2014; 24: 1670–751.
3.
FlynnRW, BonellieSR, JungRT. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab2010; 95: 186–93.
4.
TigasS, IdicullaJ, BeckettG. Is excessive weight gain after ablative treatment of hyperthyroidism due to inadequate thyroid hormone therapy?Thyroid2000; 10: 1107–11.
5.
SamuelsMH, KolobovaI, SmeraglioA. Effects of levothyroxine replacement or suppressive therapy on energy expenditure and body composition. Thyroid2016; 26: 347–55.
6.
ItoM, MiyauchiA, HisakadoM. Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy. Thyroid2017; 27: 1–7.
7.
PetersonSJ, McAninchEA, BiancoAC. Is a normal TSH synonymous with ‘euthyroidism’ in levothyroxine monotherapy?J Clin Endocrinol Metab2016; 101: 4964–73.
8.
BuneviciusR, KazanaviciusG, ZalinkeviciusR. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med1999; 340: 424–9.
9.
Escobar-MorrealeHF, del ReyFE, ObregonMJ. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology1996; 137: 2490–502.
10.
BiondiB, WartofskyL. Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism. J Clin Endocrinol Metab2012; 97: 2256–71.
11.
PanickerV, SaravananP, VaidyaB. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab2009; 94: 1623–29.
12.
CastagnaMG, DenticeM, CantaraS. DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 Levels in thyroid-deficient patients. J Clin Endocrinol Metab2017; 102: 1623–30.
13.
PearceCJ, HimsworthRL. Total and free thyroid hormone concentrations in patients receiving maintenance replacement treatment with thyroxine. BMJ1984; 288: 693–95.
14.
NordenstromA, MarcusC, AxelsonM. Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11beta-hydroxysteroid dehydrogenase reductase activity. J Clin Endocrinol Metab1999; 84: 1210–13.
15.
ToftAD. Thyroid hormone replacement – one hormone or two?N Engl J Med1999; 340: 469–70.
16.
JonklaasJ, BurmanKD. Daily administration of short-acting liothyronine is associated with significant triiodothyronine excursions and fails to alter thyroid-responsive parameters. Thyroid2016; 26: 770–78.
17.
BornsteinSR, AllolioB, WiebkeA. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab2016; 101:364.
18.
HershmanJM. A deiodinase 2 polymorphism may lower serum T3 and tissue T3 in levothyroxine-treated patients. Clin Thyroidol2017; 29: 338–40.
